{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T05:19:00Z","timestamp":1771910340396,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.bjid.2018.04.003","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T00:58:39Z","timestamp":1525913919000},"page":"186-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil"],"prefix":"10.1016","volume":"22","author":[{"given":"Vinicius Lins","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena Hiemisch Lobo","family":"Borba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Wiens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Lucia Alves","family":"Pedroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa Ferreira de Camargo","family":"Radunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia Alexandra Pontes","family":"Ivantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline Satie Oba","family":"Kuniyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2018.04.003_bib0145","unstructured":"World Health Organization (WHO). Hepatitis C Fact Sheet No 164 (Updated July 2017). Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/ [accessed 10.08.17]."},{"issue":"Suppl. 1","key":"10.1016\/j.bjid.2018.04.003_bib0150","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.bjid.2018.04.003_bib0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.bjid.2018.04.003_bib0160","series-title":"Protocolo Diretrizes Cl\u00ednico e Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es","author":"Brasil","year":"2017"},{"key":"10.1016\/j.bjid.2018.04.003_bib0165","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver (EASL)","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2018.04.003_bib0170","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C","volume":"8","author":"Sulkowski","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bjid.2018.04.003_bib0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"European Association for the Study of the Liver (EASL)","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2018.04.003_bib0180","series-title":"Recommendations for testing, managing, and treating hepatitis C","author":"American Association for the Study of Liver Diseases\/Infectious Diseases Society of America (AASLD-IDSA)","year":"2016"},{"key":"10.1016\/j.bjid.2018.04.003_bib0185","series-title":"Guidelines for the screening, care and treatment of persons with hepatitis C infection","author":"World Health Organization (WHO)","year":"2014"},{"key":"10.1016\/j.bjid.2018.04.003_bib0190","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3851\/IMP3177","article-title":"Pooled analysis of HCV genotype 1 resistance-associated substitutions in NS5A, NS3 and NS5B pre- and post-treatment with 12 weeks of daclatasvir, asunaprevir and beclabuvir","volume":"23","author":"McPhee","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2018.04.003_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2975","article-title":"Hepatitis C cure with antiviral therapy-benefits beyond the liver","volume":"21","author":"Soriano","year":"2016","journal-title":"Antivir Ther"},{"key":"10.1016\/j.bjid.2018.04.003_bib0200","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40261-017-0521-4","article-title":"Efficacy of interferon-free therapies for chronic hepatitis C: a systematic review of all randomized clinical trials","volume":"37","author":"Ferreira","year":"2017","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.bjid.2018.04.003_bib0205","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/jgh.13620","article-title":"Ledipasvir\/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: a pairwise meta-analysis","volume":"32","author":"Ferreira","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.bjid.2018.04.003_bib0210","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/jcpt.12426","article-title":"Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis","volume":"41","author":"Ferreira","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.bjid.2018.04.003_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/1516-3180.2014.1321784","article-title":"Observational studies: why are they so important?","volume":"132","author":"Mariani","year":"2014","journal-title":"Sao Paulo Med J"},{"key":"10.1016\/j.bjid.2018.04.003_bib0220","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.clinthera.2007.07.004","article-title":"Importance of observational studies in clinical practice","volume":"29","author":"Ligthelm","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.bjid.2018.04.003_bib0225","doi-asserted-by":"crossref","first-page":"727","DOI":"10.5604\/01.3001.0010.2717","article-title":"Treatment of chronic HCV infection with the new direct acting antivirals (DAA): First report of a real world experience in Southern Brazil","volume":"16","author":"Cheinquer","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.bjid.2018.04.003_bib0230","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s11096-017-0552-1","article-title":"Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience","volume":"39","author":"Medeiros","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.bjid.2018.04.003_bib0235","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/MEG.0000000000000944","article-title":"Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort","volume":"29","author":"Miotto","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.bjid.2018.04.003_bib0240","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2018.04.003_bib0245","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12879-016-2106-x","article-title":"The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease","volume":"17","author":"Young","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.bjid.2018.04.003_bib0250","doi-asserted-by":"crossref","DOI":"10.1007\/s40261-018-0624-6","article-title":"Sustained virological response in special populations with chronic hepatitis C using interferon-free treatments: a systematic review and meta-analysis of observational cohort studies","author":"Ferreira","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.bjid.2018.04.003_bib0255","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hep.25734","article-title":"Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C","volume":"56","author":"Camma","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.bjid.2018.04.003_bib0260","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3109\/1040841X.2014.970123","article-title":"Hepatitis C virus infection treatment: an era of game changer direct acting antivirals and novel treatment strategies","volume":"42","author":"Shahid","year":"2016","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.bjid.2018.04.003_bib0265","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1136\/gutjnl-2016-312012","article-title":"Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience","volume":"66","author":"El-Khayat","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.bjid.2018.04.003_bib0270","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jmv.24663","article-title":"Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection","volume":"89","author":"Kobayashi","year":"2017","journal-title":"J Med Virol"},{"key":"10.1016\/j.bjid.2018.04.003_bib0275","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","article-title":"Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort","volume":"66","author":"Calleja","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.bjid.2018.04.003_bib0280","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3851\/IMP3061","article-title":"Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials","volume":"22","author":"Arias","year":"2017","journal-title":"Antivir Ther"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867018300564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867018300564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T20:16:24Z","timestamp":1604261784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867018300564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1413867018300564"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2018.04.003","relation":{},"ISSN":["1413-8670"],"issn-type":[{"value":"1413-8670","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2018.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}